P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients. (12th March 2014) - Sylvan, S Eketorp; Lundin, J; Ipek, M; Palma, M; Karlsson, C; Hansson, L